{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157454","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.848655+00:00","generated_at":"2026-06-01T05:33:06.067659+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Annexon prices $125M public offering of common stock and pre-funded warrants","bullets":["Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.","Net proceeds expected ~$116.9M after underwriting discounts and expenses; offering closed June 7, 2024.","Underwriters granted 30-day option to purchase up to 3,000,168 additional shares.","J.P. Morgan, Jefferies, TD Cowen, BofA Securities and Wells Fargo Securities served as joint book-running managers.","Funds will support development of classical complement-mediated neuroinflammatory therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157454","json":"https://secwatch.observer/filing/0001193125-24-157454.json","markdown":"https://secwatch.observer/filing/0001193125-24-157454.md","text":"https://secwatch.observer/filing/0001193125-24-157454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524157454/0001193125-24-157454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312524157454/d841004d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:33:06.067659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}